DK1256343T3 - Flibanserin til behandlingen af extrapyramidale bevægelseslidelser - Google Patents
Flibanserin til behandlingen af extrapyramidale bevægelseslidelserInfo
- Publication number
- DK1256343T3 DK1256343T3 DK01111195T DK01111195T DK1256343T3 DK 1256343 T3 DK1256343 T3 DK 1256343T3 DK 01111195 T DK01111195 T DK 01111195T DK 01111195 T DK01111195 T DK 01111195T DK 1256343 T3 DK1256343 T3 DK 1256343T3
- Authority
- DK
- Denmark
- Prior art keywords
- parkinson
- movement disorders
- disease
- extrapyramidal movement
- treatment
- Prior art date
Links
- 208000016285 Movement disease Diseases 0.000 title abstract 3
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 title 1
- 229960002053 flibanserin Drugs 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 3
- 229940035678 anti-parkinson drug Drugs 0.000 abstract 3
- 239000000939 antiparkinson agent Substances 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical compound C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01111195A EP1256343B1 (en) | 2001-05-11 | 2001-05-11 | Flibanserin for the treatment of extrapyramidal movement disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1256343T3 true DK1256343T3 (da) | 2006-10-30 |
Family
ID=8177363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01111195T DK1256343T3 (da) | 2001-05-11 | 2001-05-11 | Flibanserin til behandlingen af extrapyramidale bevægelseslidelser |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8030314B2 (da) |
| EP (1) | EP1256343B1 (da) |
| JP (1) | JP4634008B2 (da) |
| AT (1) | ATE332138T1 (da) |
| AU (1) | AU2002310813B2 (da) |
| CA (1) | CA2444062C (da) |
| CY (1) | CY1105648T1 (da) |
| DE (1) | DE60121301T2 (da) |
| DK (1) | DK1256343T3 (da) |
| ES (1) | ES2267627T3 (da) |
| PT (1) | PT1256343E (da) |
| WO (1) | WO2002092088A2 (da) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| DE10053397A1 (de) | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| DE10138273A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Arzneimittel mit neuroprotektiver Wirkung |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| EP1578412B1 (en) * | 2002-12-23 | 2010-09-29 | Merck Frosst Company | Pharmaceutical compositions and method of treating parkinson's disease |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| KR20070014184A (ko) * | 2004-04-22 | 2007-01-31 | 베링거 인겔하임 인터내셔날 게엠베하 | 성기능 장애 치료용 신규 약제학적 조성물 ⅱ |
| US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
| JP2008511569A (ja) * | 2004-09-03 | 2008-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 注意欠如活動過多障害の治療方法 |
| JP2008538741A (ja) * | 2005-03-04 | 2008-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 鬱病の治療用及び／又は予防用の医薬組成物 |
| JP2008531714A (ja) * | 2005-03-04 | 2008-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 不安障害の治療用及び／又は予防用の医薬組成物 |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| WO2006119884A2 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
| CA2608713A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
| CA2608363A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug-induced sexual dysfunction |
| US8227476B2 (en) | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
| US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
| CA2626134C (en) | 2005-10-29 | 2013-12-24 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| JP2009526821A (ja) * | 2006-02-18 | 2009-07-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 注意欠陥多動性障害治療用の新規な医薬組成物 |
| US9066903B2 (en) | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
| JP2009541443A (ja) | 2006-06-30 | 2009-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 尿失禁及び関連疾患の治療のためのフリバンセリン |
| CA2657043A1 (en) * | 2006-07-14 | 2008-01-17 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of sexual disorders in females |
| EP2054041A2 (en) | 2006-08-14 | 2009-05-06 | Boehringer Ingelheim International GmbH | Formulations of flibanserin and method for manufacturing the same |
| CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| CN104721168A (zh) | 2006-08-25 | 2015-06-24 | 贝林格尔·英格海姆国际有限公司 | 控制释放系统及其制造方法 |
| US8722682B2 (en) | 2006-12-20 | 2014-05-13 | Sprout Pharmaceuticals, Inc. | Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity |
| DE102007009264A1 (de) * | 2007-02-26 | 2008-08-28 | Ellneuroxx Ltd. | 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen |
| PE20091188A1 (es) * | 2007-09-12 | 2009-08-31 | Boehringer Ingelheim Int | Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen |
| CA2686480A1 (en) | 2008-12-15 | 2010-06-15 | Boehringer Ingelheim International Gmbh | New salts |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU734872B2 (en) * | 1996-12-02 | 2001-06-21 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating movement disorders |
| GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
| FR2768338B1 (fr) * | 1997-09-17 | 1999-10-15 | Synthelabo | Compositions pharmaceutiques contenant un inhibiteur de la monoamine oxydase et leur application en therapeutique |
-
2001
- 2001-05-11 DE DE60121301T patent/DE60121301T2/de not_active Expired - Lifetime
- 2001-05-11 EP EP01111195A patent/EP1256343B1/en not_active Expired - Lifetime
- 2001-05-11 ES ES01111195T patent/ES2267627T3/es not_active Expired - Lifetime
- 2001-05-11 AT AT01111195T patent/ATE332138T1/de active
- 2001-05-11 DK DK01111195T patent/DK1256343T3/da active
- 2001-05-11 PT PT01111195T patent/PT1256343E/pt unknown
-
2002
- 2002-05-10 JP JP2002589005A patent/JP4634008B2/ja not_active Expired - Fee Related
- 2002-05-10 AU AU2002310813A patent/AU2002310813B2/en not_active Ceased
- 2002-05-10 US US10/473,525 patent/US8030314B2/en not_active Expired - Fee Related
- 2002-05-10 WO PCT/EP2002/005182 patent/WO2002092088A2/en not_active Ceased
- 2002-05-10 CA CA2444062A patent/CA2444062C/en not_active Expired - Fee Related
-
2006
- 2006-10-05 CY CY20061101438T patent/CY1105648T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8030314B2 (en) | 2011-10-04 |
| US20040180904A1 (en) | 2004-09-16 |
| WO2002092088A2 (en) | 2002-11-21 |
| AU2002310813B2 (en) | 2008-04-03 |
| WO2002092088A3 (en) | 2003-01-30 |
| CA2444062C (en) | 2011-02-22 |
| EP1256343B1 (en) | 2006-07-05 |
| DE60121301D1 (de) | 2006-08-17 |
| JP4634008B2 (ja) | 2011-02-16 |
| PT1256343E (pt) | 2006-11-30 |
| JP2004529175A (ja) | 2004-09-24 |
| EP1256343A1 (en) | 2002-11-13 |
| ES2267627T3 (es) | 2007-03-16 |
| CA2444062A1 (en) | 2002-11-21 |
| ATE332138T1 (de) | 2006-07-15 |
| CY1105648T1 (el) | 2010-12-22 |
| DE60121301T2 (de) | 2007-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1256343T3 (da) | Flibanserin til behandlingen af extrapyramidale bevægelseslidelser | |
| NO2025027I1 (no) | Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget. | |
| CY1109861T1 (el) | Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης | |
| ATE235895T1 (de) | Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis | |
| JP4219399B2 (ja) | 分散性錠剤 | |
| EA200301165A1 (ru) | Лекарственное средство на основе оксикодона | |
| PT1256340E (pt) | Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson | |
| BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
| DE50005529D1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| ATE544447T1 (de) | Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung | |
| EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
| CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
| DE50203456D1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| AR022589A1 (es) | UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER | |
| EA200600817A1 (ru) | Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты) | |
| DE60102590T2 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
| EA200600603A1 (ru) | Оральная система доставки лекарственного препарата | |
| BRPI0412364A (pt) | composição farmacêutica sólida, compreendendo amisulpride | |
| BRPI0412430A (pt) | polipeptìdeo agonista do receptor de zot e zonulina | |
| CA2455621A1 (en) | Use of (r/s)-(-/+) or (s)-(+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane for the treatment of extrapyramidal movement disorders | |
| SE0001916D0 (sv) | Novel formulation | |
| RU2002127006A (ru) | Новое применение (r)-(-)-2-[5-(4-фторофенил)-3-пиридилметиламинометил]-хромана и его физиологически приемлемых солей | |
| DE602006012962D1 (de) | Pharmazeutische Zubereitungen von Ciprofloxacin | |
| NO20061515L (no) | Anvendelse av okskarbazepin for behandling av diabetisk neurpatisk smerte og forbedring av sovn |